Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.
Neoadjuvant Systemic Therapy for HER2+ eBC: Clinical Considerations and Evolving Modalities
June 29th 2023Panelists expand upon the most important clinical factors that inform selection amongst available systemic therapy regimens in the neoadjuvant setting of HER2+ eBC, comment on the potential for treatment de-escalation in lower-risk patients, and discuss exciting treatments on the horizon.
Fertility Preservation in Breast Cancer: Use of GnRH Agonists
Comprehensive insight to available gonadotropin-releasing hormone (GnRH) agonists in breast cancer and the role they play when thinking about fertility preservation.
Overview of Fertility Preservation Strategies in Breast Cancer Care
Key opinion leaders on breast cancer management provide a broad overview of fertility preservation strategies available to patients.
Dr Raghav on the Rationale Behind DESTINY-CRC02 in HER2+ mCRC
June 23rd 2023Kanwal P. S. Raghav, MBBS, MD, discusses the rationale behind the phase 2 DESTINY-CRC02 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with metastatic colorectal cancer (mCRC) with HER2 amplification or overexpression.
Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm
June 22nd 2023Prithviraj Bose, MD, discusses the development of non-myelosuppressive JAK inhibitors for patients with myelofibrosis, where the future of combination therapy is headed in this population, and the importance of enrolling patients in clinical trials that are tailored to their disease subset and treatment needs.
Addressing Chemotherapy-Induced Menopause in Patients With Breast Cancer
Focused discussion on the incidence of chemotherapy-induced menopause in patients receiving treatment for their breast cancer.
Prevalence of Premenopausal Patients With Breast Cancer
Expert oncologists Matteo Lambertini, MD, PhD, and Virginia Kaklamani, MD, DSc, reflect on the subset of patients with breast cancer who are premenopausal and how that impacts their approach to disease management.
DESTINY-CRC02 Trial Continues to Support the Use of T-DXd in HER2+ Metastatic CRC
June 19th 2023Kanwal Pratap Singh Raghav MBBS, MD, discusses data from DESTINY-CRC01 that supported the DESTINY-CRC02 trial, key efficacy and safety data from the trial, and the importance of identifying patients with HER2-positive CRC who may benefit from ADCs like T-DXd in clinical practice.